Versius vs CORI in 2026

Versius

CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data.

On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.

CORI

Smith+Nephew's CORI Surgical System is a compact, surgeon-controlled handheld robotics platform for orthopedic knee surgery and the handheld, imageless archetype of the orthopedic sub-cohort. It is imageless (no pre-operative CT or MRI): the surgeon paints the joint surface intra-operatively to build a 3D bone model, then uses a handheld robotic bur whose cutting speed and exposure are robotically controlled to the surgical plan, with optical navigation.

Its small footprint positions it for ambulatory surgery centers and outpatient ORs. It is AI-augmented but surgeon-controlled, not autonomous. A critical verified-vs-claimed distinction aggregators routinely blur: CORI's robotic burring is cleared for the knee only (total, partial/unicompartmental, and revision knee); its hip capability is navigation-only (RI.HIP NAVIGATION, cleared January 2022), not robotic burring.

Made by Smith+Nephew (LSE: SN; NYSE: SNN). As enterprise B2B surgical equipment, there is no consumer price.